NCT00283764WithdrawnPhase 3
A Phase 3, 12-Week, Parallel-Design Study Comparing The Safety, Efficacy, and Ease Of Use Of Xalatan When Self-Administered By Subjects With Open-Angle Glaucoma Or Ocular Hypertension Using Either A Conventional Dropper Bottle Or A Forced-Flow Delivery Device
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.0 sitesStarted: January 30, 2006Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Withdrawn
- Sponsor
- Primary Endpoint
- Intra-ocular pressure (IOP) level in the study eye.
Study Overview
Brief Summary
Compare the antihypertensive efficacy of two methods for instilling Xalatan eyedrops
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes
Exclusion Criteria
- •History of closed/barely open anterior chamber angle or a history of angle closure
Outcomes
Primary Outcomes
Intra-ocular pressure (IOP) level in the study eye.
Secondary Outcomes
- Successful eyedrop self-deliveries
- Ease of eyedrop administration
- Change in safety assessments throughout the study period
- Subject preference for the method of drop delivery
Investigators
Similar Trials
Withdrawn
Phase 2
Corneal Versus Conjunctival Delivery Using a Delivery DeviceGlaucoma, Open-AngleOcular HypertensionNCT00143429Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Completed
Phase 4
Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.Glaucoma, Open-AngleOcular HypertensionNCT00140062Pfizer329
Completed
Not Applicable
Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN®Glaucoma,Open-AngleOcular HypertensionNCT00486252Pfizer's Upjohn has merged with Mylan to form Viatris Inc.996
Completed
Phase 4
Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy VolunteersGlaucomaNCT00468988Alcon Research30
Completed
Phase 4
A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle GlaucomaGlaucoma, Open-AngleOcular HypertensionNCT00647101Pfizer's Upjohn has merged with Mylan to form Viatris Inc.600